Advancement in LC-MS to address DMPK challenges for novel modalities

DATE

Previous Date: October 24, 2024

New Date: October 31, 2024

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes

Overview

Due to unforeseen technical issues, we have rescheduled the “Advancement in LC-MS to Address DMPK Challenges for Novel Modalities" webinar to October 31, 2024, at 11:00 a.m. ET. Our speakers will be available for the live Q&A session.

Novel synthetic drug modalities, like macrocyclic peptides, GLP-1 receptor agonist and proteolysis targeting chimeras (PROTACs^®) are rapidly emerging as novel drug modalities for challenging therapeutic targets. Although synthetic in nature, these modalities fall outside Lipinski’s rule of five, thus posing additional ADME challenges, requiring novel approaches for successful lead optimization programs. Recent advancement in Liquid Chromatography High Resolution Mass Spectrometry (LC-HRMS) technology have proven successful in increasing throughput for DMPK assays, as well as confidently identifying metabolic soft spots.

This webinar will showcase a novel approach developed by Merck & Co. on using the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer to increased throughput of combined stability testing and metabolite identification, enabling sample multiplexing to speed up the development of macrocyclic peptide drugs. Additionally, the benefit of intelligently acquired MSn fragmentation on the Thermo Scientific™ Orbitrap™ Ascend BioPharma Tribrid™ mass spectrometer for confident PROTACs^® metabolite soft spot identification edition will be presented.

Key Learning Objectives:

Recent advancement in liquid chromatography mass spectrometry to address DMPK challenges for compounds beyond Lipinski’s “rule of five”
Strategies to increase throughput in the development of macrocyclic peptide drugs DMPK assays
Benefits of multi-stage fragmentation techniques for confident PROTAC^® metabolic soft spot identification

Who Should Attend:

DMPK scientists working on peptide/cyclic peptide, PROTACs^®and undruggable targets
Researchers interested in strategies to improve ADME/DMPK properties of cyclic peptides and PROTACs^®
DMPK scientist interested novel LC-MS approach to speed DMPK assays

Brought to you by:

Speakers

Congliang Sun, Ph.D.
Sr. Scientist,
Merck & Co.

Sven Hackbusch, Ph.D.
Senior Applications Scientist,
Thermo Fisher Scientific

Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group

Registration

Forwarded this event? Clear the form

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars